Denali Therapeutics Inc (DNLI) Stock Price, Quote & News

Company Profile

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement thera...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 866 8547

Website: www.denalitherapeutics.com

Address:

161 Oyster Point Boulevard, South San Francisco, United States

ZacksResearch Mar. 11 at 4:23 PM

$DNLI just ripped 11.8% in a month — but the real catalyst is still ahead. Investors are watching an April 5, 2026 FDA decision on tividenofusp alfa for Hunter syndrome, which could be a major growth driver and is clearly fueling the recent momentum. 👀 Big biotech catalysts can move fast — see the full setup before the decision 👉 https://www.zacks.com/stock/news/2882427/denali-gains-118-in-a-month-buy-sell-or-hold-the-stock?cid=sm-stocktwits-2-2882427-teaser-36991&ADID=SYND_STOCKTWITS_TWEET_2_2882427_TEASER_36991

0 · Reply

ZacksResearch Mar. 11 at 3:23 PM

$DNLI surges 11.8% in a month — what’s fueling the rally? 🚀 Investor optimism is high for the potential approval of tividenofusp alfa for Hunter syndrome, with a key FDA decision expected on April 5, 2026. Positive Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations underscore the drug's potential. 📈 See what makes the investment case strong for DNLI 👉 https://www.zacks.com/stock/news/2882427/denali-gains-118-in-a-month-buy-sell-or-hold-the-stock?cid=sm-stocktwits-2-2882427-body-36992&ADID=SYND_STOCKTWITS_TWEET_2_2882427_BODY_36992

0 · Reply

BullDonald Mar. 11 at 2:20 PM

$DNLI Order Placed ! Fill it . I need more.

0 · Reply

CharlieeMungerTWITS Mar. 10 at 6:08 PM

$DNLI LETS GO

1 · Reply

CharlieeMungerTWITS Mar. 10 at 5:09 PM

$DNLI $30 stock if fda approves Hunter syndrome indication

0 · Reply

NorthStarStats Mar. 10 at 2:30 AM

Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $PYXS Score: 95.00 | >350% implied upside|Earnings, $AVGO Score 95.00 |100B+ in AI chip revenue expected, $GHRS Score: 95.00 |Solid Cash Runway| $42 upgrade, $DNLI Score: 95.00 |PDUFA tividenofusp alfa April 5, $LYV Score 73.00 |DOJ Setlmnt|Venue Nation Expansion

0 · Reply

BullDonald Mar. 9 at 7:41 PM

$DNLI Call started !

0 · Reply

Doozio Mar. 9 at 3:34 PM

chop chop huckleberries wen the DAWN of a 🧠👀 became $DNLI of da 🐑 during 🐒🍌🧠⏰♾️

0 · Reply

BullDonald Mar. 7 at 1:51 PM

$DNLI - 80%+ institution ownership, - Big Pharma backing the pipelines, - The sentiment it Optimistic for the approval. - Low volume fluctuation caused by the Retail swinging it for a dollar or two. - Strong support level is 18. Should Bounce hard after shaking the paper hands. If it tests 18, I may add some to my position.🚀

0 · Reply

dgbio Mar. 7 at 2:02 AM

$DNLI Prasad is fired again

0 · Reply

FDA reversals leave investors worrying about the fates of other experimental drugs

DNLI MRNA RGNX WVE

Feb 26, 2026, 4:01 PM EST - 13 days ago

Market Cap	3.40B
Revenue (ttm)	0.00
Net Income (ttm)	-512.54M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,140,900
Avg Vol	1,650,552
Day's Range	N/A - N/A
Shares Out	158.59M
Stochastic %K	92%
Beta	1.02
Analysts	Strong Sell
Price Target	$32.93